Large-scale testing (Phase 3)Study completedNCT04799249
What this trial is testing
Trilaciclib, a CDK 4/6 Inhibitor, in Patients Receiving Gemcitabine and Carboplatin for Metastatic Triple-Negative Breast Cancer (TNBC)
Who this might be right for
TNBC - Triple-Negative Breast CancerBreast Cancer
G1 Therapeutics, Inc. 194